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Cannabinoids, the bioactive constituents of cannabis, exert a wide array of effects on the 70 
brain by engaging type-1 cannabinoid receptor (CB1R). Accruing evidence supports that 71 
cannabinoid action relies on context-dependent factors such as the biological 72 
characteristics of the target cell, suggesting that cell population-intrinsic molecular cues 73 
modulate CB1R-dependent signaling. Here, by using a yeast two-hybrid-based high-74 
throughput screening, we identified BiP as a potential CB1R-interacting protein. We next 75 
found that CB1R and BiP interact specifically in vitro, and mapped the interaction site 76 
within the CB1R C-terminal (intracellular) domain and the BiP C-terminal (substrate-77 
binding) domain-α. BiP selectively shaped agonist-evoked CB1R signaling by blocking 78 
an “alternative” Gq/11 protein-dependent signaling module, while leaving the “classical” 79 
Gi/o protein-dependent inhibition of the cAMP pathway unaffected. In situ proximity 80 
ligation assays conducted on brain samples from various genetic mouse models of 81 
conditional loss or gain of CB1R expression allowed to map CB1R-BiP complexes 82 
selectively on terminals of GABAergic neurons. Behavioral studies using cannabinoid-83 
treated BiP+/- mice supported that CB1R-BiP complexes modulate cannabinoid-evoked 84 
anxiety, one of the most frequent undesired effects of cannabis. Altogether, by 85 
identifying BiP as a CB1R-interacting protein that controls receptor function in a 86 
signaling pathway- and neuron population-selective manner, our findings may help to 87 
understand the striking context-dependent actions of cannabis in the brain. 88 




Significance Statement 90 
Cannabis use is increasing worldwide, so innovative studies aimed to understand its complex 91 
mechanism of neurobiological action are warranted. Here, we found that cannabinoid CB1 92 
receptor (CB1R), the primary molecular target of the bioactive constituents of cannabis, 93 
interacts specifically with an intracellular protein called BiP. The interaction between CB1R 94 
and BiP occurs selectively on terminals of GABAergic (inhibitory) neurons, and induces a 95 
remarkable shift in the CB1R-associated signaling profile. Behavioral studies conducted in 96 
mice support that CB1R-BiP complexes act as fine-tuners of anxiety, one of the most frequent 97 
undesired effects of cannabis use. Our findings open a new conceptual framework to 98 
understand the striking context-dependent pharmacological actions of cannabis in the brain. 99 





Preparations of the hemp plant Cannabis sativa L. have been used by humankind for 102 
millennia. During the last decades there has been a strong renaissance in the study of 103 
the molecular and pharmacological bases of cannabinoid action, and, in concert, many 104 
countries have approved the use of cannabinoid-based medicines and standardized 105 
preparations of medicinal cannabis (Hill, 2015; Abrams, 2018). Both the therapeutic and 106 
the adverse effects of cannabis are mostly attributed to a single molecule, ∆9-107 
tetrahydrocannabinol (THC) (Mechoulam et al., 2014). This compound engages and 108 
activates two specific G protein-coupled receptors (GPCRs), designated as cannabinoid 109 
CB1 receptor (CB1R) and cannabinoid CB2 receptor (CB2R) (Pertwee et al., 2010). 110 
CB1R is one of the most abundant GPCRs in the mammalian brain (Katona and Freund, 111 
2008; Pertwee et al., 2010; Dudok et al., 2015). It mediates a large number of 112 
pharmacological effects of THC, and, upon binding endocannabinoids (anandamide and 113 
2-arachidonoylglycerol), participates in the physiological control of multiple processes 114 
such as motor behavior, learning and memory, fear and anxiety, pain, food intake, and 115 
energy metabolism (Piomelli, 2003; Mechoulam et al., 2014). 116 
The precise molecular mechanism of CB1R action remains unsolved. For 117 
example, CB1R couples to the inhibitory family of heterotrimeric G proteins (Gi/o), but its 118 
expression and signaling efficacy differs remarkably between excitatory and inhibitory 119 
neurons (Steindel et al., 2013), which could explain, at least in part, the widely reported 120 
biphasic effects elicited by THC and other CB1R agonists (Bellocchio et al., 2010; Rey et 121 
al., 2012; Mechoulam and Parker, 2013). Likewise, under different cellular settings, 122 
CB1R can signal through other G protein families as Gq/11 and Gs (Lauckner et al., 2005; 123 
Priestley et al., 2017). Furthermore, CB1R activation protects neurons from death in a 124 




of brain cancer cells (Velasco et al., 2012). How these striking differences in signaling 126 
efficacy, G-protein coupling, and biological response occur is not understood. Altogether, 127 
these observations suggest a cell population-selective action of CB1R colligated to the 128 
physiopathological context of the target cell expressing the receptor. Understanding how 129 
CB1R evokes such varying responses is important to clarify the neurobiological role of 130 
the endocannabinoid system and, potentially, to improve the design of CB1R-targeted 131 
therapies. 132 
Interaction with regulatory proteins represents one of the pivotal molecular 133 
processes by which GPCR-evoked signaling is affected. Diverse subsets of these 134 
interacting proteins assist GPCRs during biosynthesis, trafficking, activation, 135 
desensitization, and degradation (Maurice et al., 2011). Aside from the most ubiquitous 136 
GPCR-associated proteins (i.e., G proteins, β-arrestins, and GPCR kinases), specific 137 
interacting partners have been identified for particular types of receptors (e.g., NHERF 138 
proteins for adrenergic receptors and others, and Homer proteins for metabotropic 139 
glutamate receptors and others) (Wheeler et al., 2007; Magalhaes et al., 2012) . 140 
Regarding CB1R, several intracellular proteins (led by CRIP1a) (Howlett et al., 2010; 141 
Guggenhuber et al., 2016), as well as membrane-anchored GPCRs (e.g., serotonin 5-142 
HT2A and adenosine A2A receptors) (Viñals et al., 2015; Moreno et al., 2018), have been 143 
proposed as receptor interactors. However, most studies on these putative protein 144 
complexes have been conducted in vitro, and only subtle effects have been unraveled 145 
so far in vivo. 146 
Here, we hypothesized that unidentified neuron population-specific CB1R-147 
interacting proteins modulate cannabinoid signaling in the brain. By using a yeast two-148 
hybrid (Y2H)-based approach, complemented with a wide array of molecular, genetic, 149 




modulator of biased signaling of CB1R, and defined the molecular features, signal-151 
transduction consequences, neuroanatomical mapping, and behavioral outcomes of the 152 





Materials and Methods 155 
 156 
Gene constructs 157 
Y2H vectors were generated by PCR and subsequent restriction cloning by using 158 
pGBT9 and pGAD as vectors (ClonTech, TaKaraBio, Mountain View, CA, USA). Short 159 
amino-acid stretches (CB1R mutants) were ligated by using long annealing 160 
oligonucleotides with protruding overhangs. The cDNA encoding full-length BiP was 161 
provided by Dr. Valerie Petegnief (Institute for Biomedical Research of Barcelona, 162 
Barcelona, Spain), and expression vectors encoding non-tagged (pcDNA3.1+ backbone; 163 
Thermo Fisher Scientific, Waltham, MA, USA), GFP-tagged (pEGFP-C2 backbone; 164 
ClonTech) and recombinant bacterial-expression [pBH4 backbone (Merino-Gracia et al., 165 
2016b)] versions were built as well by PCR and restriction cloning. BiP-∆IR comprised 166 
BiP amino acids 1-308. 3XFLAG-tagged versions were obtained by using IVA cloning 167 
(García-Nafría et al., 2016) with pcDNA3.1+ plasmids as templates. pcDNA3.1-HA-168 
CB1R, pcDNA3.1-CB1R-myc, CB1R-Rluc, CB1R-GFP and pcDNA3.1-A1R constructs 169 
had been generated previously in our laboratory. Single phosphomimetic mutants of 170 
CB1R-CTD, as well as the CB1R-S452D-Rluc construct, were obtained through 171 
Quickchange mutagenesis with the aforementioned plasmids as templates. pcDNA3.1-172 
CB2R was provided by Dr. Cristina Sánchez (Complutense University of Madrid, Madrid, 173 
Spain) and used to construct the corresponding Y2H vector. pCEFL-GFP and pCEFL-174 
GFP-GRK2 plasmids were given by Dr. J. Silvio Gutkind (University of California San 175 
Diego, CA, USA). All constructs were validated by Sanger sequencing before use. 176 




Yeast two-hybrid (Y2H) 178 
Screening of the library was performed following the manufacturer’s instructions 179 
(MatchMaker system, TaKaraBio, Mountain View, CA, USA). Plasmids of positive 180 
transformants were isolated and subsequently sequenced by standard procedures. 181 
Directed Y2H experiments were conducted as previously reported (Merino-Gracia et al., 182 
2016a). Yeasts were transformed with plasmids containing the GAL4 binding domain 183 
and the GAL4 activation domain following a lithium acetate-based method. Double 184 
transformants were placed on Leu/Trp/His-deficient plates in the presence of 12 mM 3-185 
aminotriazole (triple dropout plates) as well as only Leu/Trp-deficient plates. Interacting 186 
proteins expressed within the same yeast allowed colonies that could rescue growth in 187 
triple-dropout plates and were capable to hydrolyse X-Gal. 188 
 189 
Protein expression and purification 190 
pBH4 plasmids encoding His6-tagged BiP, BiP-IR (amino acids 497-654) or CB1R-CTD 191 
(amino acids 400-472) were used to transform competent BL21 DE3 Escherichia coli. 192 
Typically, 2 liters of bacterial culture in 2xYT (16 g/L tryptone, 10 g/L yeast extract, 5 g/L 193 
NaCl, pH 7.0) were used for recombinant protein expression. Protein expression was 194 
induced by addition of 0.5 mM isopropyl 1-thio-β-D-galactopyranoside (Panreac Química 195 
S.A.U., Barcelona, Spain) and incubation overnight at 30 °C with 250 rpm aeration rate. 196 
Bacterial cells were pelleted and frozen at −20 °C until used for protein purification. 197 
Bacterial cell lysis was conducted in ice-cold lysis buffer (100 mM Tris-HCl, 100 198 
mM NaCl, 10 mM imidazole, pH 7.0) with continuous shaking in the presence of 199 
protease inhibitors (1 μg/mL aprotinin, 1 μg/mL leupeptin, 200 μM PMSF), 0.2 g/l 200 
lysozyme and 5 mM β-mercaptoethanol, followed by 4 cycles of sonication on ice. The 201 




Recombinant His6-tagged proteins were sequentially purified on a nickel-nitrilotriacetic 203 
acid affinity column. After extensive washing (50 mM Tris, 100 mM NaCl, 25 mM 204 
imidazole, pH 7.0), proteins were eluted with elution buffer (50 mM Tris, 100 mM NaCl, 205 
250 mM imidazole, pH 7.0; supplemented with protease inhibitors). Protein purity was 206 
confirmed by SDS-PAGE and Coomassie Brilliant Blue or Silver staining. Pure protein 207 
solutions were concentrated by centrifugation in Centricon® tubes (Millipore, Burlington, 208 
MA, USA). 209 
 210 
Fluorescence polarization 211 
His6-tagged CB1R-CTD (amino acids 400-472) was labelled with 5-212 
(Iodoacetamido)fluorescein (5-IAF) by standard procedures. Briefly, the FITC dye was 213 
dissolved in DMSO and the labelling reaction was performed in sodium bicarbonate 214 
buffer, pH 9.0, with a 3-fold molar excess of dye for 1 hour at 25 °C, protected from light. 215 
Subsequently, a 1.00-Da cut-off dialysis membrane was used to eliminate non-reacted 216 
5-IAF compound. After extensive dialysis, the concentration of the labeled peptide was 217 
calculated using the value 68,000 cm–1M–1 as the molar extinction coefficient of the dye 218 
at pH 8.0 at 494 nm. Saturation binding experiments were performed essentially as 219 
described (Merino-Gracia et al., 2016a) with a constant concentration of 100 nM 5-IAF-220 
CB1R-CTD. The fluorescence polarization values obtained were fitted to the equation 221 
(FP-FP0) = (FPMax -FP0)[BiP or BiP-IR]/(Kd + [BiP or BiP-IR]), where FP is the measured 222 
fluorescence polarization, FPMax is the maximal fluorescence polarization value, FP0 is 223 
the fluorescence polarization in the absence of added BiP or BiP-IR, and Kd is the 224 
dissociation constant as determined with GraphPad Prism v8.0.1 (GraphPad Software, 225 
San Diego, CA, USA). FP was expressed as milli-FP units (mFP; net FP x 1,000). Each 226 




Cell culture, transfection, and incubation 228 
The HEK-293T cell line was obtained from the American Type Culture Collection 229 
(Manassas, VA, USA). Cells were grown in DMEM supplemented with 10% FBS 230 
(Thermo Fisher Scientific), 1% penicillin/streptomycin, 1 mM Na-pyruvate, 1 mM L-231 
glutamine, and essential medium non-essential amino acids solution (diluted 1/100) (all 232 
from Invitrogen, Carlsbad, CA, USA). Cells were maintained at 37ºC in an atmosphere 233 
with 5% CO2 in the presence of the selection antibiotic (zeocin at 0.22 mg/mL, Thermo 234 
Fisher Scientific), and were periodically checked for the absence of mycoplasma 235 
contamination. Cell transfections were conducted with polyethyleneimine (Polysciences 236 
inc. Warrington, PA, USA) in a 4:1 mass ratio to DNA according to the manufacturer’s 237 
instructions. Double transfections were performed with equal amounts of the two 238 
plasmids. In all cases, 48 hours after transfection, cells were washed twice in quick 239 
succession, detached, and harvested for further procedures. To control cell number, 240 
protein concentration in the samples was determined with a Bradford assay kit (Bio-Rad, 241 
Hercules, CA, USA). 242 
Drug treatments to assess CB1R-evoked signaling were conducted as follows. A 243 
10 cm-diameter plate of transfected cells was trypsinized and seeded on a 6-well plate 244 
at a density of 0.75x106 cells per well. Six hours later, cells were serum-starved 245 
overnight. Then, WIN-55,212-2 (Tocris Bioscience, Bristol, UK; 100 nM final 246 
concentration) or vehicle (DMSO, 0.1% v/v final concentration) was added for 5, 10 or 15 247 
minutes. Gαq/11 inhibition was achieved by adding YM-254890 (Focus Biomolecules, 248 
LLC, Plymouth Meeting, PA, USA; 1 µM final concentration) or vehicle (DMSO, 0.1% v/v 249 
final concentration) 30 minutes before WIN-55,212-2 (100 nM final concentration) or 250 




triplicate. Cells were subsequently washed with ice-cold PBS, snap-frozen in liquid 252 
nitrogen, and harvested at -80 °C for Western blot analyses. 253 
 254 
In situ proximity ligation assay (PLA) 255 
BiP-CB1R complexes were detected by using the Duolink In Situ PLA Detection Kit 256 
(Sigma-Aldrich, St. Louis, MO, USA) following the manufacturer’s instructions. 257 
Synaptosomal preparations were incubated with a rabbit-anti-CB1R antibody (1:500, 258 
Frontier-Institute, Ishikari, Hokkaido, Japan #CB1-Rb-Af530) and a mouse anti-259 
GRP78/BiP antibody (1:500, Santa Cruz Biotechnology; Dallas, TX, USA #sc-376768). 260 
Negative controls were performed with just one primary antibody. Ligations and 261 
amplifications were performed with In Situ Detection Reagent Red (Sigma-Aldrich), and 262 
coverslips were mounted in DAPI-containing mounting medium. Samples were analyzed 263 
with a Leica SP2/SP8 confocal microscope (Leica Microsystems, Mannheim, Germany). 264 
For each field of view a stack of two channels (one per staining) and 9 to 13 Z-stacks 265 
with a step size of 0.3 µm were acquired with an 63x oil-immersion objective and 266 
processed with ImageJ software (National Institutes of Health, Bethesda, MD). 267 
Representative images for each condition were prepared for figure presentation by 268 
applying color adjustments uniformly with Adobe Photoshop vCS6 (Berkeley, CA, USA). 269 
For PLA imaging in brain sections, mice were deeply anesthetized and 270 
immediately perfused transcardially with PBS followed by 4% 271 
paraformaldehyde/phosphate buffer. Brains were removed and post-fixed overnight in 272 
the same solution, cryoprotected by immersion in 10, 20, 30% gradient sucrose (24 273 
hours for each sucrose gradient) at 4 °C, and then frozen in dry ice-cooled 274 
methylbutane. Serial coronal or sagittal cryostat sections (30 μm-thick) through the 275 




experiments were performed. Immediately before the assay, mouse brain sections were 277 
mounted on glass slides, washed in PBS, permeabilized with PBS containing 0.01% 278 
Triton X-100 for 10 minutes, and successively washed with PBS. Interactions were 279 
detected with Duolink In Situ PLA Detection and In Situ Detection Reagent Red Kits. A 280 
mixture of the primary antibodies [mouse anti-GRP78/BiP antibody (1:100, Santa Cruz 281 
Biotechnology #sc-376768) and rabbit anti-CB1R antibody (1:100, Thermo Scientific, 282 
Fremont, CA, USA #PA1-745)] was used. Samples were analyzed in a Leica SP2 283 
confocal microscope (Leica Microsystems) equipped with an apochromatic 63x oil-284 
immersion objective (1.4 numerical aperture), and a 405 nm and a 561 nm laser lines. 285 
For each field of view a stack of two channels (one per staining) and 9 to 13 Z-stacks 286 
with a step size of 1 µm were acquired. Images were opened and processed with Image 287 
J software (NIH). Quantification of cells containing one or more red dots versus total 288 
cells (blue nuclei) was determined by using the Fiji package (http://pacific.mpi-cbg.de). 289 
Nuclei and red dots were counted on the maximum projections of each image stack. 290 
After getting the projection, each channel was processed individually. The blue nuclei 291 
and red dots were segmented by filtering with a median filter, subtracting the 292 
background, enhancing the contrast with the Contrast Limited Adaptive Histogram 293 
Equalization (CLAHE) plug-in, and finally applying a threshold to obtain the binary image 294 
and the regions of interest. 295 
 296 
Bioluminescence Resonance Energy Transfer (BRET) 297 
HEK-293T cells growing in 6-well plates were transiently cotransfected with a constant 298 
amount of cDNA encoding the receptor fused to Rluc protein and with increasingly 299 
amounts of GFP-BiP-IR. To quantify protein-GFP expression, cells (20 μg total protein) 300 




fluorescence was read in a Fluostar Optima fluorimeter (BMG Labtech, Offenburg, 302 
Germany) equipped with a high-energy xenon flash lamp using a 10-nm bandwidth 303 
excitation filter at 410 nm for protein-GFP reading. Protein-fluorescence expression was 304 
determined as fluorescence of the sample minus the fluorescence of cells expressing 305 
only the BRET donor. For BRET measurements, cells (20 μg of protein) were distributed 306 
in 96-well microplates (Corning 3600, White plates; Sigma) and BRET signal was 307 
collected 1 minute after addition of 5 μM DeepBlueC (Molecular Probes, Eugene, OR) 308 
using a Mithras LB 940 reader (Berthold Technologies, Bad Wildbad, Germany), that 309 
allows the integration of the signals detected in the short-wavelength filter at 400 nm and 310 
the long-wavelength filter at 510 nm. To quantify receptor-Rluc expression luminescence 311 
readings were also performed after 10 minutes of adding 5 μM DeepBlueC (Molecular 312 
Probes, Eugene, OR). The net BRET is defined as [(long-wavelength emission)/(short-313 
wavelength emission)]-Cf where Cf corresponds to [(long-wavelength emission)/(short-314 
wavelength emission)] for the Rluc construct expressed alone in the same experiment. 315 
BRET is expressed as milli BRET units (mBU; net BRET x 1,000). In BRET curves 316 
BRET was expressed as a function of the ratio between fluorescence and luminescence 317 
(GFP/Rluc). To calculate maximal BRET from saturation curves, data was fitted using a 318 
non-linear regression equation and assuming a single phase with GraphPad Prism 319 
software v8.0.1. Each representative curve shown is the mean of three internal 320 
replicates. 321 
 322 
Western blot and co-immunoprecipitation 323 
Samples for Western blotting were prepared on ice-cold lysis buffer (50 mM Tris-HCl, 1 324 
mM EDTA, 1 mM EGTA, 0.1% Triton X-100, 50 mM NaF, 10 mM Na-glycerophosphate, 325 




by centrifugation at 12,000g for 15 minutes (4 °C) and total protein was quantified using 327 
the Bradford assay. Then, 5 to 20-µg aliquots of total protein, boiled for 5 minutes at 95 328 
°C and prepared in 5x Laemmli Sample Buffer, were resolved by using SDS-PAGE and 329 
transferred to PVDF membranes. Membranes were blocked with 5% defatted milk (w/v) 330 
or 5% BSA (w/v) in TBS-Tween-20 (0.1%) for 1 hour and incubated overnight with the 331 
following antibodies and dilutions: anti-phospho-ERK1/2 (1:1,000, CST, Danvers, MA, 332 
USA #9101), anti-ERK1/2 (1:1,000, CST #4696), anti-phospho-p70S6K (1:1,000, 333 
CST#9206), anti-phospho-CREB (1:1,000, CST #9198), anti-BiP (1:1,000, Sigma-Aldrich 334 
#G8918), anti-GFP (1:1000, Thermo Scientific #MA5-15256), anti-α-tubulin (1:10,000, 335 
Sigma-Aldrich #T9026), anti-β-actin (1:10,000, Sigma-Aldrich #A5441), anti-FLAG M2 336 
(1:1,000, Sigma-Aldrich #F3165), anti-HA (1:1,000, CST #3724S), and anti-calnexin 337 
(1:1,000, Santa Cruz Biotechnology #SC-6465). All antibodies were prepared in TBS-338 
Tween-20 (0.1%) with 5% BSA (w/v). Membranes were then washed three times with 339 
TBS-Tween-20 (0.1%), and HRP-labeled secondary antibodies, selected according to 340 
the species of origin of the primary antibodies (Sigma-Aldrich #NA-931-1 and #NA-341 
934V), were added for 1 hour at a 1:5,000 dilution in TBS-Tween-20 (0.1%) at room 342 
temperature. Finally, protein bands were detected by incubation with an enhanced 343 
chemiluminescence reagent (Bio-Rad) and densitometric analysis of the relative 344 
expression of the protein of interest vs. the corresponding loading control was performed 345 
with ImageJ software. Western blot images were cropped for clarity. Electrophoretic 346 
migration of molecular weight markers is depicted on the left-hand side of each blot. 347 
For co-immunoprecipitation experiments, 48 hours after transfection, cells were 348 
lysed on ice-cold GST buffer (50 mM Tris-HCl, 10% glycerol v/v, 100 mM NaCl, 2 mM 349 
MgCl2, 1% v/v NP-40, pH 7.4), supplemented with protease inhibitors. Cell lysates were 350 




quantified with Bradford assay. Twenty-µg aliquots were collected to check for 352 
transfection levels (whole-cell lysates), and 1 mg of total protein was incubated with 20 353 
µL of HA-agarose beads (Thermo Scientific #26181) or FLAG M2 agarose beads 354 
(Sigma-Aldrich #A2220) for 2-4 hours at 4 °C with a final protein concentration of 1 355 
mg/mL. Beads were subsequently washed 3 times with lysis buffer and eluted with 30 µL 356 
of 2x Laemmli Sample Buffer without β-mercaptoethanol and 5 minutes of sample 357 
boiling. Ten µL of the elution was further analyzed by Western blotting as previously 358 
described. GFP immunoprecipitation was performed analogously, with a pre-clarification 359 
step on 30 µL of Protein A/G (GE Healthcare, Chicago, IL, USA #17061801), followed by 360 
overnight incubation of the remaining supernatant with 1 µg of anti-GFP antibody 361 
(produced in-home), and 2-4 hours of incubation with 30 µL of Protein A/G mixture. The 362 
rest of the steps were identical to those mentioned above. 363 
 364 
Dynamic mass redistribution (DMR) 365 
The cell-signaling signature was determined using an EnSpire® Multimode Plate Reader 366 
(PerkinElmer, Waltham, MA, USA) by a label-free technology. Cellular mass movements 367 
induced upon receptor activation were detected by illuminating the underside of the 368 
biosensor with polychromatic light and measured as changes in wavelength of the 369 
reflected monochromatic light that is a sensitive function of the index of refraction. The 370 
magnitude of this wavelength shift (herein measured in picometers) is directly 371 
proportional to the amount of DMR. Briefly, 24 hours before the assay, cells were 372 
seeded at a density of 10,000 cells per well in 384-well sensor microplates with 30 μL 373 
growth medium and cultured for 24 h (37°C, 5% CO2) to obtain 70-80% confluent 374 
monolayers. Previous to the assay, cells were washed twice with assay buffer (HBSS 375 




0.1% DMSO in the reader at 24 °C. Hereafter, the sensor plate was scanned, and a 377 
baseline optical signature was recorded before adding 10 μL of the test compound 378 
dissolved in assay buffer containing 0.1% DMSO. Then, DMR responses were 379 
monitored along time, and kinetic data were analysed using EnSpire Workstation 380 
Software v4.10. Each representative curve shown is the mean of three internal 381 
replicates. 382 
 383 
Phosphoprotein array 384 
Cells transfected with CB1R-GFP and BiP-IR (or control) plasmids were treated with 385 
WIN-55,212-2 (100 nM final concentration) or vehicle (DMSO, 0.1% v/v final 386 
concentration) as described above for 5 and 15 minutes. Samples from two independent 387 
experiments were processed separately by using 350 µg of total protein per 388 
experimental condition, following the instructions of the Proteome Profiler Human 389 
Phospho-Kinase Array Kit (R&D, Bio-techne, Minneapolis, MN, USA #ARY003C). 390 
Densitometric analysis of the relative phosphorylation levels vs. the corresponding 391 
housekeeping controls and between WIN-55,212-2/vehicle treatments was performed 392 
with ImageJ software and the Protein Array Analyzer toolset. 393 
 394 
Cellular and subcellular fraction preparations 395 
Membrane preparations for G protein-coupling assays were obtained from HEK-293T-396 
cell pellets or adult mouse-hippocampus tissue specimens. Frozen samples were 397 
thawed at 4 °C and homogenized with a glass/teflon grinder (IKA labortechnik, Satufen, 398 
Germany), 10 strokes at maximum speed, in 30 volumes of homogenization buffer (250 399 
mM sucrose, 50 mM Tris-HCl, 1 mM EGTA, 3 mM MgCl2, 1 mM DTT, pH 7.4). The 400 




discarded, and the supernatants were re-centrifuged at 40,000g for 10 minutes at 4 °C. 402 
The resultant pellets were resuspended in 20 volumes of ice-cold centrifugation buffer 403 
(50 mM Tris-HCl, 1 mM EGTA, 3 mM MgCl2, 1 mM DTT, pH 7.4) with a glass stick and 404 
recentrifuged at 40,000g for 10 minutes at 4 °C. The pellets obtained were then 405 
resuspended in 5 volumes of centrifugation buffer. Protein content was determined by 406 
the Bradford method. Finally, aliquots of 0.5, 1.0 and 2.0 mg protein were centrifuged at 407 
21,000g for 15 minutes at 4 °C. The supernatant layer was carefully discarded, and the 408 
pellets were stored at -80 °C until assayed. 409 
Total, cytosolic and ER fractions from hippocampus, cortex and striatum of the 410 
adult mouse brain were obtained by lysing the corresponding regions through sonication 411 
in 2 mL of ice-cold MTE buffer (270 mM D-mannitol, 10 mM Tris-HCl, 0.1 mM EDTA, pH 412 
7.4). Tissue extracts were centrifuged (1,400g, 10 minutes, 4 °C), and the supernatant 413 
(total cell lysate) was re-centrifuged (15,000g, 10 minutes, 4 °C) to separate the pelleted 414 
mitochondrial crude fraction. Isolation of ER from cytosol was achieved by loading the 415 
sample in a sucrose gradient (2 M – 1.5 M – 1.3 M) and conducting an 416 
ultracentrifugation step (152,000g, 70 minutes, 4 °C). The ER fraction appears as a band 417 
at the 1.5 M/1.3 M sucrose interphase, while the cytosolic fraction remains at the top of 418 
the tube. Both fractions were collected, in the case of the ER with the aid of a syringe 419 
with a 20G needle, and the ER fraction was further purified by an additional 420 
ultracentrifugation step (126,000g, 45 minutes, 4 °C). The ER-containing pellet was 421 
resuspended in 100 µL of PBS and immediately frozen. Likewise, aliquots of total cell 422 
lysate and cytosolic fractions were collected throughout the process and immediately 423 
frozen. Samples were kept at -80 ºC for Western blot analysis. 424 
Striatal, hippocampal and cortical synaptosomes were isolated from adult CB1R-425 




fixed in 4% paraformaldehyde and characterized as described (Martín et al., 2010). PLA 427 
assays were conducted as described above. 428 
 429 
Antibody-capture [35S]GTPγS scintillation proximity assay 430 
Specific activation of different subtypes of Gα protein subunits (Gαi1, Gαi2, Gαi3, Gαo, 431 
Gαq/11, Gαs, Gαz, and Gα12/13) was determined by using a homogeneous protocol of 432 
[35S]GTPγS scintillation proximity assay coupled to the use of the following antibodies: 433 
mouse monoclonal anti-Gαi1 (1:20, Santa Cruz Biotechnology #sc-56536), rabbit 434 
polyclonal anti-Gαi2 (1:20; Santa Cruz Biotechnology #sc-7276), rabbit polyclonal anti-435 
Gαi3 (1:30, Antibodies on-line #ABIN6258933), mouse monoclonal anti-Gαo (1:40, Santa 436 
Cruz Biotechnology #sc-393874), mouse monoclonal anti-Gαq/11 (1:20, Santa Cruz 437 
Biotechnology #sc-515689), rabbit polyclonal anti-Gαs (1:20, Santa Cruz Biotechnology 438 
#sc-383), rabbit polyclonal anti-Gαz (1:20, Santa Cruz Biotechnology #sc-388), and 439 
rabbit polyclonal anti-Gα12/13 (1:20 Santa Cruz Biotechnology sc-28588). [35S]GTPγS 440 
binding was measured in 96-well isoplates (PerkinElmer Life Sciences, Maanstraat, 441 
Germany) and a final volume of 200 μL containing 1 mM EGTA, 3 mM MgCl2, 100 mM 442 
NaCl, 0.2 mM DTT, 50 mM Tris–HCl, pH 7.4, 0.4 nM [35S]GTPγS, 10 µg of protein per 443 
well, and different concentrations of GDP (between 50 and 100 µM) depending on the 444 
Gα subunit subtype tested. At the end of the 2-hour incubation period (at 30 °C), 20 µL 445 
of 1% Igepal plus 0.1% SDS was added to each well, and plates were incubated at 22 446 
°C for 30 minutes with gentle agitation. The specific antibody for the Gα subunit of 447 
interest was then added to each well before an additional 90-minute incubation period at 448 
room temperature. Polyvinyltoluene (PVT) SPA beads coated with protein A 449 
(PerkinElmer, S.L., Tres Cantos, Madrid, Spain) were then added (0.75 mg of beads per 450 




Finally, plates were centrifuged (5 minutes at 1,000g), and the bound radioactivity was 452 
detected on a MicroBeta TriLux scintillation counter (PerkinElmer S.L., Tres Cantos, 453 
Madrid, Spain). To determine their effect on [35S]GTPγS binding to the different Gα 454 
subunit subtypes in the different experimental conditions, a single submaximal 455 
concentration (10 µM) of WIN-55,212-2 was used, either alone or in the presence of the 456 
CB1R antagonist O-2050 (10 µM) as control. Nonspecific binding was defined as the 457 
remaining [35S]GTPγS binding in the presence of 10 µM unlabelled GTPγS. For each Gα 458 
protein, specific [35S]GTPγS binding values were transformed to percentages of basal 459 
[35S]GTPγS binding values (those obtained in the presence of vehicle). 460 
 461 
Determination of cAMP concentration 462 
Homogeneous time-resolved fluorescence energy transfer (HTRF) assays were 463 
performed using the Lance Ultra cAMP kit (PerkinElmer). HEK-293T cells (1,000 per 464 
well), growing in medium containing 50 µM zardeverine, were incubated in triplicate for 465 
15 minutes in white ProxiPlate 384-well microplates (PerkinElmer) at 25°C with vehicle 466 
or WIN-55,212-2 (100 nM final concentration) before adding vehicle or forskolin (0.5 μM 467 
final concentration) and incubating for 15 additional minutes. Fluorescence at 665 nm 468 
was analyzed on a PHERAstar Flagship microplate reader equipped with an HTRF 469 
optical module (BMG Lab technologies, Offenburg, Germany). 470 
 471 
Animals 472 
All the experimental procedures used were performed in accordance with the guidelines 473 
and with the approval of the Animal Welfare Committees of Universidad Complutense de 474 
Madrid and Comunidad de Madrid, as well as of Universitat de Barcelona and 475 




Government and the European Commission. BiP+/- (herein referred to as BiP-HET) mice 477 
were purchased from The Jackson Laboratory (Bar Harbor, ME, USA #019549). We also 478 
used CB1Rfloxed/floxed (herein referred to as CB1R-floxed) mice, CB1Rfloxed/floxed;CMV-Cre 479 
(herein referred to as CB1R-KO) mice, conditional CB1Rfloxed/floxed;Nex1-Cre (herein referred 480 
to as Glu-CB1R-KO) mice, and conditional CB1Rfloxed/floxed;Dlx5/6-Cre (herein referred to as 481 
GABA-CB1R-KO) mice (Monory et al., 2006); as well as Stop-CB1R, Stop-CB1REIIa-Cre 482 
(herein referred to as CB1R-RS) mice, conditional Stop-CB1RNex1-Cre (herein referred to 483 
as Glu-CB1R-RS) mice, and conditional Stop-CB1RDlx5/6-Cre (herein referred to as GABA-484 
CB1R-RS) mice, to allow CB1R gene-expression rescue from a CB1R-null background 485 
(Ruehle et al., 2013; De Salas-Quiroga et al., 2015). Animal housing, handling and 486 
assignment to the different experimental groups were conducted as described (Ruiz-487 
Calvo et al., 2018). Adequate measures were taken to minimize pain and discomfort of 488 
the animals. 489 
 490 
In situ hybridization histochemistry 491 
For in situ hybridization histochemistry (ISHH), 14 μm-thick coronal whole-brain tissue 492 
sections were obtained from adult C57BL/6 mice (Janvier Laboratories, France), cut on 493 
a microtome-cryostat (Microm HM500 OM, Walldorf, Germany), thaw-mounted on 3-494 
aminopropyltriethoxysilane (APTS)-coated slides (Sigma-Aldrich), and kept at -20 °C 495 
until further processing. The oligonucleotides complementary to the mRNAs encoding 496 
BiP, CB1R, and GABAergic or glutamatergic markers are listed in Table 1. 497 
Oligonucleotides for each mRNA were labeled at their 3´-end by using [α-33P]dATP 498 
(3000 Ci/mmol, Hartmann Analytic GmbH, Braunschweig, Germany). Labeled probes 499 
were purified on ProbeQuant G-50 Micro Columns (GE Healthcare, Buckinghamshire, 500 




autoradiography, hybridized sections were exposed to Biomax-MR (Kodak, Rochester, 502 
NY, USA) films for 1-10 days at -70 °C with intensifying screens. Double in situ-503 
hybridized sections were processed as described (Reyes-Irisarri et al., 2007). They were 504 
exposed in the dark for 4-6 weeks at 4°C. Images from autoradiograms were obtained 505 
by using a Wild 420 macroscope (Leica Microsystems, Wetzlar, Germany) equipped with 506 
a digital camera (DXM1200 F, Nikon, Tokyo, Japan) and ACT-1 Nikon software. 507 
Microphotography was performed with an Olympus BX51 Stereologic Microscope 508 
(Olympus, Tokyo, Japan) equipped with a digital camera (DP71, Olympus) or with a 509 
Zeiss Axioplan microscope (Germany) equipped with an Olympus XC50 digital camera. 510 
Figures were assembled using Adobe Photoshop (Adobe Systems, San Jose, CA, 511 
USA). Only contrast and brightness were uniformly adjusted in order to optimize images. 512 
 513 
Behavioral tests 514 
Adult male mice (3-4 month-old) were injected i.p. with vehicle (1% v/v DMSO in 1:18 v/v 515 
Tween-80/saline solution) or 10 mg/kg THC (THC Pharm). The “cannabinoid tetrad” was 516 
assessed, starting 30 minutes after injection, following standard guidelines (Metna-517 
Laurent et al., 2017). First, the open-field test was conducted for 10 minutes in an arena 518 
of 70 x 70 cm. To evaluate anxiety-like behaviors, the number of entries of the animal 519 
into the central part of the arena (25 x 25 cm) relative to total ambulation was assessed, 520 
one entry being counted when the animal had placed at least both forelimbs in the 521 
square. Next, analgesia was assessed as the latency to paw licking in the hot-plate 522 
paradigm at a constant temperature of 52 °C. Then, for the catalepsy test, the animal 523 
was placed with both forelimbs leaning on a bar situated at a height of 3.5 cm. Immobility 524 
was considered maximal when the animal exceeded 60 seconds of immobility, and null 525 




performed, and the maximal immobility time was selected as the representative value. 527 
Finally, body temperature was measured with a rectal thermometer and compared to the 528 
basal, pre-injection value. 529 
The elevated plus maze test was evaluated 4 hours after acute i.p. injection of 530 
vehicle or THC (10 mg/kg). The maze consisted of a cross-shaped plastic device with 531 
two opposite open arms (30-cm long, 5-cm wide) and two opposite closed arms (30 cm-532 
long, 5-cm wide, 16-cm tall walls), connected by a central structure (5 x 5 cm), and 533 
elevated 50 cm from the floor. Each mouse was placed in the center of the maze, facing 534 
one of the open arms, and the exploratory behavior of the animal was video-recorded for 535 
5 minutes. The number and duration of entries was measured separately for the open 536 
arms and the closed arms. One arm entry was registered when the animal had placed 537 
both forepaws in the arm. 538 
In all cases, animals were assigned randomly to the different treatment groups, 539 
and all experiments were performed in a blinded manner for genotype and 540 
pharmacological treatment. All tests were video-recorded for subsequent blinded 541 
analysis using Smart3.0 v3.00.6 Software (Panlab, Barcelona, Spain). 542 
 543 
Experimental design and statistical analyses 544 
Unless otherwise specified, data are presented as mean ± SEM. Statistical comparisons 545 
were conducted by one-way or two-way ANOVA with Tukey’s post hoc test, or by 546 
Student’s t test, as indicated in each case. All datasets were tested for normality 547 
(Kolmogorov-Smirnov’s test) and homoscedasticity (Levene’s test) prior to analysis. For 548 
clarity, only p values lower than 0.05 were considered statistically significant. The 549 
sample size for each experiment was estimated on the basis of previous studies 550 




and motor-behavior approaches. Subsequent power analysis was conducted for each 552 
parameter by using IBM SPSS software (IBM France, Bois-Colombes, France). The 553 
number of biological replicates (e.g., number of mice, number of cell cultures) is 554 
provided in the corresponding figure legends. The number of technical replicates (e.g., 555 
number of Y2H assays, number of incubations within each cell culture, number of 556 
sections microscopically analyzed per mouse brain, number of behavioral trials per 557 
mouse) is provided in the corresponding figure legends or in the corresponding Materials 558 
and Methods subsections. All the experiments conducted with animals are presented as 559 
dot plots. Graphs and statistics were generated by GraphPad Prism v8.0.1. 560 






BiP interacts with CB1R in vitro 564 
To identify new CB1R-interacting intracellular proteins, we challenged the receptor’s 565 
carboxyl-terminal domain (CTD; amino acids 408 to 472) to a cDNA library containing 566 
>106 different clones by means of a Y2H system. One particular cDNA clone, comprising 567 
amino acids 497 to 654 of the protein BiP (hereafter “BiP-interacting region”; BiP-IR), 568 
provided an unequivocally positive outcome (Fig. 1A). BiP, also known as GRP78 or 569 
Hspa5, belongs to the highly conserved Hsp70 family of molecular chaperones. These 570 
proteins consist of two different domains: an N-terminal nucleotide-binding domain 571 
(NBD) with ATPase activity, and a C-terminal substrate-binding domain (SBD). The 572 
SBD, in turn, is composed of a β-sandwich domain (SBDβ) and an α-helical lid (SBDα), 573 
which are interlinked by a hydrophobic stretch (Wieteska et al., 2017). It is generally 574 
believed that ATP-assisted, BiP-mediated protein refolding proceeds when hydrophobic 575 
peptides bind to a conserved groove in the SBDβ domain of BiP. Conversely, here, we 576 
found that CB1R-CTD interacts essentially with the lid domain in the absence of the 577 
groove. Specifically, according to the reported structures (Yang et al., 2015, 2017), BiP-578 
IR would span the entire SBDα and two strands of the SBDβ (Fig. 1A, bottom diagram). 579 
We next aimed to validate the molecular specificity of the interaction between 580 
CB1R-CTD and BiP-IR. First, by using directed Y2H assays, we delimitated the BiP-IR-581 
binding site to a restricted 23 amino-acid stretch (residues 449-472) at the edge of 582 
CB1R-CTD (Fig. 1B). Second, we found that the CTD of CB2R, the GPCR with the 583 
highest sequence homology to CB1R, did not bind BiP-IR (Fig. 1B). Third, as the 584 
phosphorylation state of specific S and T residues in the CTD of a GPCR can determine 585 




phosphomimetic mutant (S/T → D) within CB1R-CTD, and found that only the S452D 587 
point mutation, which is precisely located in the last 23 amino-acid portion of CB1R, 588 
impaired the association (Table 2). Fourth, we expressed recombinant CB1R-CTD, BiP-589 
IR and BiP, and found that BiP and BiP-IR bind CB1R-CTD with a similar high affinity, as 590 
measured by fluorescence polarization-based protein-protein binding assays (Fig. 1C). 591 
We subsequently conducted experiments in HEK-293T cells. First, co-592 
immunoprecipitation studies showed that (i) CB1R-CTD, and specifically its 449-460 593 
amino-acid stretch, was sufficient to bind BiP-IR (Fig. 1D); (ii) full-length CB1R also 594 
interacted with both BiP and BiP-IR (Fig. 1E); and (iii) BiP-IR exhibited little association 595 
with the S452D point-mutant of CB1R-CTD (Fig. 1F). Second, BRET experiments 596 
conducted with an Rluc-tagged version of CB1R also supported the protein-protein 597 
interaction (Fig. 1G, upper panel), and adding non-GFP-tagged versions of BiP as 598 
competitors decreased the BRET peak only when the BiP-IR was present (Fig. 1G, 599 
lower panel). Moreover, there was no overt binding between GFP-BiP-IR and CB1R-600 
Rluc when the S452D single mutation was introduced in the receptor (Fig. 1G, upper 601 
panel). 602 
Taken together, these data show that BiP interacts specifically with CB1R in 603 
vitro, both in purified-protein assays and in HEK-293T cells. 604 
 605 
BiP modulates CB1R-evoked signaling 606 
Dynamic mass redistribution (DMR) is a powerful tool to assess the overall signal 607 
triggered by the agonist-evoked activation of a particular receptor in living cells (Fang et 608 
al., 2007). In fact, we and others have previously used DMR to investigate CB1R-evoked 609 
signaling (Viñals et al., 2015; Moreno et al., 2018; Navarro et al., 2020). Here, by using 610 




adding the cannabinoid receptor-selective agonist WIN-55,212-2 (Fig. 2A). Of note, co-612 
expression of full-length BiP led to a strong inhibition of CB1R signaling (Fig. 2A) but did 613 
not alter the agonist-evoked response of two other Gi/o-coupled receptors (CB2R and 614 
adenosine A1 receptor) that were used as controls (Fig. 3A). The effect of BiP on CB1R 615 
relied selectively on BiP-IR, as expressing this region rendered a comparable inhibition, 616 
and no change was found with BiP-∆IR (Fig. 2A). This effect was again subverted when 617 
the S452D point mutation was inserted in CB1R (Fig. 3B), and was also evident –though 618 
with a slower kinetics- when the endocannabinoids anandamide and 2-619 
arachidonoylglycerol) were used as receptor agonists (Fig. 2B). Given the similar 620 
behavior of full-length BiP and BiP-IR, we used only BiP-IR for further signaling 621 
experiments. 622 
CB1R activation modulates multiple signaling pathways, being cAMP/PKA, ERK 623 
and PI3K/Akt/mTORC1 the best characterized (Pertwee et al., 2010; Nogueras-Ortiz and 624 
Yudowski, 2016). We thus aimed to dissect in detail the inhibitory effect of BiP-IR on 625 
CB1R overall signaling observed in DMR assays. First, we found that BiP-IR did not alter 626 
markedly the archetypical Gαi/o-coupling profile of CB1R (Fig. 2C), nor affected the WIN-627 
55,212-2-evoked reduction of forskolin-augmented cAMP concentration (Fig. 2D). Next, 628 
we analyzed the phosphorylation (activation) state of major cellular protein kinases by 629 
using a phosphoprotein array. HEK-293T cells were transfected with the same 630 
constructs used in the aforementioned DMR assays, and subsequently treated with 631 
vehicle or WIN-55,212-2. Among the different pathways activated by the cannabinoid, 632 
BiP-IR preferentially hampered the Akt/mTORC1 pathway (as inferred from Akt1/2/3-633 
T308, PRAS40-T246 and p70S6K-T389 phosphorylation) and the ERK pathway (as 634 
inferred from ERK1/2-T202/Y204 phosphorylation) (Fig. 2E). The WIN-55,212-2-635 




and ERK pathways, was also inhibited by BiP-IR (as inferred from CREB-S133 637 
phosphorylation). We confirmed this BiP-mediated inhibition of CB1R-evoked signaling 638 
by analyzing pERK1/2-T202/Y204, pp70S6K-T389, and pCREB-S133 with conventional 639 
Western blotting (Fig. 2F). Accordingly, the PI3K inhibitor LY294002 and the MEK1 640 
inhibitor U0126 blunted the WIN-55,212-2-evoked DMR signal (Fig. 3C). 641 
To study how BiP selectively alters CB1R-mediated signaling independently of 642 
Gαi/o proteins, we evaluated the coupling of the receptor to non-Gαi/o G proteins. Of note, 643 
we found that CB1R also coupled to Gαq/11, and this association was impaired by BiP-IR 644 
(Fig. 2G). Moreover, WIN-55,212-2-mediated ERK activation was mitigated by either 645 
pharmacological blockade of Gαq/11 (with the drug YM-254890) or genetic interference of 646 
Gαq/11 signaling (with a dominant-negative GFP-GRK2 construct) (Andradas et al., 2016) 647 
(Fig. 2H). Likewise, YM-254890 and dominant-negative Gαq/11 reduced the WIN-55,212-648 
2-evoked DMR response (Fig. 2I). We next analyzed the coupling of CB1R to Gαq/11 in 649 
hippocampal extracts from adult BiP+/- (hereafter BiP-HET) and BiP+/+ (hereafter BiP-WT) 650 
mice [Note that very early embryonic lethality occurs in BiP-/- mice (Luo et al., 2006).] In 651 
line with the aforementioned data from HEK-293T cells, CB1R showed a preference for 652 
Gαq/11 coupling in BiP-HET mice compared to their BiP-WT littermates (Fig. 2J). 653 
Taken together, these data show that BiP-IR affects CB1R-evoked signaling 654 
through the selective attenuation of an “alternative” Gαq/11 protein-driven module, while 655 
leaving the “classical” Gαi/o protein-driven module essentially unaffected. 656 
 657 
CB1R-BiP complexes reside on GABAergic terminals of the mouse brain 658 
It is well established that CB1R resides largely on terminals of GABAergic neurons 659 
(Marsicano and Lutz, 1999; Katona and Freund, 2008). However, the precise 660 




Hence, we analyzed the expression of BiP mRNA in GABAergic vs. glutamatergic 662 
neurons by in situ hybridization histochemistry. BiP mRNA was localized throughout the 663 
mouse brain (Fig. 4A), showing a more ubiquitous expression pattern than CB1R mRNA 664 
(Fig. 4B). Of note, nearly all the hippocampal high CB1R mRNA-expressing cells were 665 
also positive for BiP mRNA [93.7 ± 1.7% in the CA1/3 areas and 94.6 ± 3.4% in the 666 
dentate gyrus (DG)] (Figs. 4C and 4D). In the CA1/3 hippocampal areas, as reported for 667 
CB1R mRNA (Marsicano and Lutz, 1999), BiP mRNA showed a high co-localization with 668 
GAD65/67 mRNA (81.6 ± 4.4% of the BiP-positive cells co-expressed GAD65/67) (Figs. 669 
5A and 5B), while co-localization with vGluT1 mRNA was hardly detectable in the 670 
scattered BiP-expressing cells adjacent to the BiP/vGluT1 mRNA-enriched pyramidal 671 
cell layer (<1% of the BiP-positive cells co-expressed vGluT1) (Figs. 5C and 5D). In the 672 
DG, the distribution of BiP mRNA between disseminated GAD65/67 mRNA-expressing 673 
neurons (Figs. 5A and 5B) and vGluT1 mRNA-expressing neurons (Figs. 5C and 5D) 674 
was more balanced, although again with a preference towards inhibitory cells (47.0 ± 675 
9.9% and 30.0 ± 7.2% of the BiP-positive cells co-expressed GAD65/67 or vGluT1, 676 
respectively). 677 
The most widely reported subcellular localization of BiP is the endoplasmic 678 
reticulum (ER) lumen, while CB1R is largely located at the plasma membrane, and its 679 
CTD faces the cytoplasm since its biosynthesis starts on the ER. To assess this 680 
apparent inconsistency, we performed subcellular fractionation experiments in mouse 681 
brain samples. Analysis of hippocampal, striatal, and cortical tissue extracts showed that 682 
BiP is present not only in the ER but also in the cytosolic fraction (Figs. 6A and 6B). This 683 
observation supports the notion that cytoplasmic BiP binds to CB1R-CTD, and aligns 684 
with previous reports showing that not all BiP functions can be attributed to its interaction 685 




Yoon et al., 2018), and that a population of BiP molecules is found adjacent to the 687 
plasma membrane (Tsai et al., 2015). As the majority of CB1R resides at the 688 
presynapse, where it controls neurotransmitter release (Piomelli, 2003), we also 689 
evaluated whether CB1R-BiP complexes are present in this subcellular location. PLA 690 
analyses revealed a pronounced positive signal in synaptosomes from the hippocampus, 691 
striatum, and cortex of CB1R-WT mice, but not of CB1R-KO littermates (Fig. 6C). 692 
Next, to obtain a detailed neuroanatomical map of CB1R-BiP protein complexes, 693 
we conducted in situ PLA assays on brain slices from various genetic mouse models of 694 
conditional loss or gain of CB1R expression (Fig. 7A). We first used hippocampi from 695 
conditional CB1R-KO models (Marsicano et al., 2002) (Figs. 7B, 7D, 7E and 7G). PLA 696 
experiments conducted on hippocampal sections from control adult CB1Rfloxed/floxed 697 
(hereafter CB1R-floxed) mice showed that 63.2 ± 4.7% and 62.9 ± 11.2% of the cells 698 
contained positive puncta in the DG and CA1, respectively. This signal was strongly 699 
reduced in sections from CB1Rfloxed/floxed;CMV-Cre (hereafter CB1R-KO) mice (DG: 14.8 ± 700 
5.0%; CA1: 18.8 ± 4.5%). In conditional knockout mice in which the gene encoding 701 
CB1R had been selectively deleted from forebrain GABAergic neurons 702 
(CB1Rfloxed/floxed;Dlx5/6-Cre; hereafter GABA-CB1R-KO), we found a notable decrease in the 703 
percentage of cells expressing positive dots (DG: 31.9 ± 6.2%; CA1: 33.9 ± 7.8%). In 704 
contrast, sections from mice in which the gene encoding CB1R had been selectively 705 
deleted from dorsal telencephalic glutamatergic neurons (CB1Rfloxed/floxed;Nex1-Cre; hereafter 706 
Glu-CB1R-KO) displayed a similar pattern of PLA staining than their CB1R-floxed 707 
counterparts (DG: 58.6 ± 5.9%; CA1: 60.8 ± 1.1%). Comparable overall data were 708 
obtained in sections from mouse striatum and cortex (Figs. 8A, 8B, 8D, 8E and 8G). 709 
We subsequently made use of a Cre-mediated, lineage-specific, CB1R gene 710 




(De Salas-Quiroga et al., 2015; De Giacomo et al., 2020a) (Figs. 7C, 7D, 7F and 7G). 712 
PLA assays in hippocampal sections from these mice showed, as expected, a marginal 713 
CB1R-KO-like background signal (DG: 20.1 ± 3.2%; CA1: 21.2 ± 3.2%). In line with the 714 
data from conditional knockout mice, rescuing CB1R gene expression with a constitutive 715 
Cre recombinase (Stop-CB1REIIa-Cre, hereafter, CB1R-RS) restored CB1R-BiP 716 
complexes to the levels of control CB1R-floxed mice (DG: 59.6 ± 5.5%; CA1: 58.5 ± 717 
5.8%). This effect was paralleled in brain sections from conditionally-rescued Stop-718 
CB1RDlx5/6-Cre (hereafter, GABA-CB1R-RS) mice (DG: 58.1 ± 9.6%; CA1: 56.9 ± 5.5%) 719 
but not from conditionally-rescued Stop-CB1RNex1-Cre (hereafter, Glu-CB1R-RS) mice 720 
(DG: 21.1 ± 3.2%; CA1: 20.0 ± 2.5%). As in the aforementioned conditional knockout 721 
mouse experiments, these CB1R gene expression-rescue data in the mouse 722 
hippocampus displayed a similar global pattern in the striatum and cortex (Figs. 8C, 8D, 723 
8F and 8G). 724 
Taken together, these data support the interaction between CB1R and BiP in 725 
three key regions of the mouse brain, and, more specifically, a restricted occurrence of 726 
CB1R-BiP complexes in GABAergic neurons. 727 
 728 
BiP affects CB1R function in vivo 729 
THC induces numerous behavioral changes in laboratory animals and humans. The 730 
combination of hypolocomotion, analgesia, catalepsy and hypothermia, usually 731 
designated as the “cannabinoid tetrad”, has evolved as a powerful tool to identify 732 
pharmacological or genetic interventions that target CB1R (Martin, 1986; Metna-Laurent 733 
et al., 2017). Previous studies have shown that these four behavioral traits rely 734 
selectively on the activation of CB1R molecules located on various populations of 735 




GABAergic interneurons, thus allowing a neurobiological correlate between CB1R 737 
cellular expression and function (Monory et al., 2007; De Giacomo et al., 2020a). We 738 
studied the “cannabinoid tetrad” in BiP-HET and BiP-WT littermates (Fig. 9A), and found 739 
that acute THC injection (10 mg/kg, i.p.) elicited the four archetypical effects of the 740 
“cannabinoid tetrad” to the same extent in BiP-HET and BiP-WT animals (Fig. 9, left 741 
panels). In addition, following a 5-day sustained treatment, BiP-HET and BiP-WT mice 742 
developed a comparable tolerance to THC (Fig. 9, right panels). 743 
As the CB1R-BiP complexes reside selectively on GABAergic neurons (see 744 
above), it is not surprising that the deletion of a BiP allele does not modify any of the 745 
classical “cannabinoid tetrad” behavioral traits. Of note, anxiety-like behaviors induced 746 
by cannabinoid intoxication have been shown to rely selectively on the activation of 747 
CB1R molecules located on GABAergic interneurons (Rey et al., 2012; De Giacomo et 748 
al., 2020a, 2020b). Because the open-field test of the “cannabinoid tetrad” can also be 749 
used to define anxious phenotypes by evaluating the relative ambulation of the animals 750 
across the center of the arena (Seibenhener and Wooten, 2015), we conducted these 751 
analyses in our experimental setting. A single THC injection reduced the ambulation of 752 
the mice across the center of the arena equally in BiP-HET and BiP-WT mice (Fig. 10A, 753 
left panel). However, after a 5-day continuing THC treatment, the ambulation across the 754 
centre of the arena remained lowered by acute THC in BiP-HET mice but not in their 755 
BiP-WT littermates (Fig. 10A, right panel). 756 
To provide further support to the control of CB1R-mediated anxiety by BiP, we 757 
used the elevated plus maze test, a widely recognized measure of anxiety that served 758 
originally to define the anxiogenic activity of the CB1R pool located on GABAergic 759 
neurons (Rey et al., 2012). We injected BiP-WT and BiP-HET mice with vehicle or THC 760 




mice but a significant anxiogenic effect in BiP-HET littermates, as evidenced by the 762 
decrease in both the number of entries (Fig. 10B, left panel) and the time of permanence 763 
(Fig. 10B, right panel) in the open arms of the device. 764 
Taken together, these data support that BiP, by interacting with CB1R on 765 
GABAergic neurons, modulates anxiety-like behaviors upon cannabinoid administration. 766 





Here, we show that BiP interacts specifically with CB1R-CTD. BiP is known to interact 769 
with some GPCRs during their folding (Siffroi-Fernandez et al., 2002; Mizrachi and 770 
Segaloff, 2004; Langer et al., 2008), and has been found associated to melanocortin 771 
MC4 receptors at the plasma membrane (Yoon et al., 2018). The CB1R-BiP interaction 772 
occurs between a short amino-acid stretch in the CB1R-CTD and the BiP-SBD domain. 773 
The latter domain, to our knowledge, has never been implicated in the binding of BiP to 774 
membrane receptors. As the protein-binding/refolding function of BiP is usually ascribed 775 
to its SBDβ domain (Yang et al., 2015, 2017), we cannot rule out that additional proteins 776 
interact through this region onto the CB1R-BiP complexes. The BiP-interacting region in 777 
CB1R partially overlaps with the putative C-terminal helix 9 of the receptor (Ahn et al., 778 
2009), which might serve as an axon-targeting signal and a potential protein-protein 779 
interaction site (Fletcher-Jones et al., 2019). How the synaptic trafficking of CB1R could 780 
be controlled by BiP is therefore an intriguing possibility that remains to be explored. 781 
Additionally, the BiP-binding region of CB1R contains a specific phosphorylation site 782 
(S452) that regulates this protein-protein interaction, and may conceivably participate in 783 
agonist-induced receptor signaling and subsequent internalization (Daigle et al., 2008). 784 
In fact, a high-throughput phosphoproteomic study identified this phosphorylated residue 785 
in the mouse brain (Wiśniewski et al., 2010). The lack of reported mutations in this BiP-786 
binding region of CB1R (https://gpcrdb.org), along with its evolutionary conservation, 787 
further supports its biological importance. 788 
CB1R-evoked signaling is markedly affected upon BiP binding. This finding 789 
contrasts with the subtle effect of CRIP1a on CB1R/G-protein coupling (Blume et al., 790 
2015), and with the BiP-mediated facilitation of melanocortin MC4 receptor activation 791 




various key CB1R-evoked effects in the brain (Rubino et al., 2007; Guegan et al., 2013; 793 
Puighermanal et al., 2013; Blázquez et al., 2020). However, the possible relevance of 794 
Gαq/11 protein in CB1R neurobiological action remains unclear (Diez-Alarcia et al., 2016). 795 
Our data unveil an unprecedented functional coupling of CB1R signaling to Gαq/11, as 796 
well as a selective hampering effect of BiP on it. Interestingly, regions analogous to 797 
CB1R helix 9, which overlaps with the BiP-binding site, have been reported to act as 798 
Gαq/11-binding sites in rhodopsin (Murakami and Kouyama, 2008) and bradykinin B2 799 
receptor (Piserchio et al., 2005). Thus, it is conceivable that in CB1R the binding of BiP 800 
constitutes a competitive steric impediment to achieve Gαq/11 binding and activation. 801 
Our detailed mapping of CB1R-BiP complexes in the mouse brain shows that 802 
GABAergic neurons constitute the foremost cell population expressing these complexes. 803 
This is in line with a previous high-throughput proteomic study showing that BiP co-804 
immunoprecipitates with CB1R in mouse GABAergic neurons (Mattheus et al., 2016). It 805 
is worth noting that, despite their low CB1R/G-protein coupling efficacy (Steindel et al., 806 
2013), GABAergic terminals contain large amounts of CB1R (Marsicano and Lutz, 1999; 807 
Katona and Freund, 2008) likely displaying a high tonic activity (Roberto et al., 2010). 808 
Given its inhibitory role, we speculate that BiP binding may represent a counterpoint to 809 
ensure a balanced CB1R activity in the physiological control of glutamatergic/GABAergic 810 
neurotransmission. More specifically, THC-elicited anxiety relies on mTORC1 activation 811 
upon engagement of CB1R on hippocampal GABAergic interneurons (Rey et al., 2012; 812 
Puighermanal et al., 2013; De Giacomo et al., 2020a, 2020b). In addition, a role of Gαq/11 813 
protein-coupled receptors (e.g., serotonin 5-HT2C receptor) in the induction of anxiety 814 
has been suggested (Mazzone et al., 2018). Thus, we propose that the THC-evoked 815 
high-input activation of a restricted Gαq/11-coupled pool of CB1R molecules located on 816 




like behaviors, a process plausibly controlled by BiP binding to CB1R at the presynapse. 818 
This would provide an unprecedented mechanism for the spatially-selective control of 819 
CB1R signaling in the brain, and supports that favoring CB1R-BiP association would 820 
reduce anxiety, a frequent negative effect of CB1R over-activation. As CB1R-BiP 821 
complexes also reside on GABAergic neurons in other brain regions as the cortex and 822 
striatum, the possibility that BiP binding controls additional CB1R-related behaviors 823 
remains to be determined. 824 
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Figure legends 1043 
 1044 
Figure 1. BiP interacts with CB1R in vitro 1045 
A, Scheme of the Y2H experiment using CB1R-CTD (amino acids 408-472) as bait and 1046 
a human cDNA library (>106 clones) as prey. One cDNA clone (stained in blue) 1047 
contained BiP/GRP78/Hspa5 amino acids 497-654 (BiP-IR). A diagram depicting the 1048 
main structural domains of BiP/GRP78/Hspa5 is shown. B, Scheme of the Y2H 1049 
experiment using fragments of CB1R-CTD or CB2R-CTD as bait and BiP-IR as prey. C, 1050 
Fluorescence polarization-based protein-protein binding experiments using 5-IAF-1051 
labeled CB1R-CTD and increasing amounts of unlabeled BiP (upper panel) or BiP-IR 1052 
(lower panel). A representative experiment, including the gels of the purified proteins, is 1053 
shown (n=3). D, Co-immunoprecipitation experiments in HEK-293T cells expressing 1054 
fragments of GFP-CB1R-CTD and 3xFLAG-BiP-IR. Immunoprecipitation (IP) was 1055 
conducted with anti-GFP antibody. WCL: whole-cell lysate. A representative experiment 1056 
is shown (n=3). E, Co-immunoprecipitation experiments in HEK-293T cells expressing 1057 
HA-CB1R and 3xFLAG-BiP or 3xFLAG-BiP-IR. IP was conducted with anti-HA antibody 1058 
(left panel) or anti-FLAG antibody (right panel). The asterisk denotes immunoglobulin 1059 
heavy and light chains. A representative experiment is shown (n=3). F, Co-1060 
immunoprecipitation experiments in HEK-293T cells expressing GFP-CB1R-CTD wild-1061 
type or an S452D point-mutant form, along with 3xFLAG-BiP-IR. IP was conducted with 1062 
anti-GFP antibody. A representative experiment is shown (n=3). G, BRET experiments in 1063 
HEK-293T cells expressing CB1R-Rluc or CB1R-S452D-Rluc and increasing amounts of 1064 
GFP-BiP-IR (upper panel; a representative experiment is shown; n=3), together or not 1065 
with non-tagged versions of BiP, BiP-IR or BiP-∆IR as competitors (lower panel). 1066 






Figure 2. BiP modulates CB1R-evoked signaling 1070 
A, DMR experiments in HEK-293T cells expressing CB1R, together or not with BiP, BiP-1071 
IR or BiP-∆IR, and incubated with vehicle or WIN-55,212-2 (100 nM). A representative 1072 
experiment is shown (n=3). B, DMR experiments in HEK-293T cells expressing CB1R, 1073 
together or not with BiP-IR, and incubated with vehicle or endocannabinoid (10 µM; 2-1074 
AG, 2-arachidonoylglycerol; AEA, anandamide). A representative experiment is shown 1075 
(n=3). C, Coupling of CB1R to Gαi/o proteins in membrane extracts from HEK-293T cells 1076 
expressing CB1R, together or not with BiP-IR. *p<0.05 from basal (dashed line), or 1077 
#p<0.05 from control vector, by one-sample Student’s t-test or unpaired Student’s t-test, 1078 
respectively (n=3). D, cAMP concentration in HEK-293T cells expressing CB1R, together 1079 
or not with BiP-IR. Cells were incubated first for 15 min with vehicle or WIN-55,212-2 1080 
(100 nM), and then for 15 min with vehicle or forskolin (FSK; 500 nM). **p<0.01 from 1081 
vehicle, or ##p<0.01 from FSK alone, by two-way ANOVA with Tukey’s multiple 1082 
comparisons test (n=3). E, HEK-293T cells expressing CB1R, together or not with BiP-1083 
IR, were incubated for 5 or 15 min with vehicle or WIN-55,212-2 (100 nM), and cell 1084 
extracts were blotted on a phosphoprotein array. Two different times of membrane 1085 
exposure are shown to allow an appropriate visualization of the main proteins affected 1086 
(framed spots). A representative experiment is shown (n=2; membranes from vehicle-1087 
treated cells are omitted for clarity). The heat map represents values of mean fold-1088 
activation by WIN-55,212-2 over vehicle. F, Validation of some of the phosphoarray hits 1089 
by conventional Western blotting in the same cell extracts used in panel D. A 1090 
representative experiment is shown (n=2). G, Coupling of CB1R to non-Gαi/o Gα proteins 1091 




IR. *p<0.05 from basal (dashed line), or #p<0.05 from control vector, by one-sample 1093 
Student’s t-test or unpaired Student’s t-test, respectively (n=3). H, Western blotting of 1094 
phospho-ERK in HEK-293T cells expressing CB1R, and incubated for 5, 10 or 15 min 1095 
with vehicle or WIN-55,212-2 (100 nM). Upper panel: Cells were pre-incubated for 30 1096 
min with vehicle or YM-254890 (1 µM). Lower panel: Cells co-expressed control vector 1097 
(GFP) or Gαq/11 dominant-negative vector (GFP-GRK2). A representative experiment is 1098 
shown (n=3). I, DMR experiments in HEK-293T cells expressing CB1R under the same 1099 
experimental conditions as in panel G. A representative experiment is shown (n=3). J, 1100 
Coupling of CB1R to Gαq/11 protein in hippocampal extracts from 3–4-month-old BiP+/+ 1101 
(BiP-WT) and BiP+/- (BiP-HET) mice. *p<0.05 from basal (dashed line), or #p<0.05 from 1102 
BiP-WT group, by one-sample Student’s t-test or unpaired Student’s t-test, respectively 1103 
(n=5-6 mice per group). 1104 
 1105 
Figure 3. Controls of specificity of the CB1R-BiP DMR experiments 1106 
A, DMR experiments in HEK-293T cells expressing CB2R, together or not with BiP, and 1107 
incubated with vehicle or the CB2R-selective agonist HU-308 (100 nM); or in HEK-293T 1108 
cells expressing A1R, together or not with BiP, and incubated with vehicle or the A1R-1109 
selective agonist PIA (50 nM). A representative experiment is shown (n=3). B, DMR 1110 
experiments in HEK-293T cells expressing CB1R-S452D, together or not with BiP, and 1111 
incubated with vehicle or WIN-55,212-2 (100 nM). A representative experiment is shown 1112 
(n=3). C, DMR experiments in HEK-293T cells expressing CB1R and incubated with 1113 
vehicle or WIN-55,212-2 (100 nM) plus U0126 (5 µM) or LY294002 (5 µM). A 1114 
representative experiment is shown (n=3). 1115 
 1116 




AB, Representative autoradiographic images of coronal sections from adult mouse brain 1118 
showing the mRNA hybridization pattern of BiP (panel A) and CB1R (panel B). CA, 1119 
cornu Ammonis; DG, dentate gyrus, Str, striatum; Cx, cortex; Cb, cerebellum. C, 1120 
Distribution of CB1R mRNA in the mouse hippocampus. i) Representative dark field 1121 
image from a section hybridized with 33P-labelled oligonucleotide probes for CB1R 1122 
mRNA. A positive signal is evident as clusters/accumulation of bright silver grains. Note 1123 
the moderate signal on the pyramidal cell layer of CA and the very intense signal on 1124 
scattered cells in the various hippocampal layers. ii, iii) Co-localization of CB1R mRNA 1125 
and BiP mRNA in cells of the stratum radiatum and stratum lacunosum moleculare of 1126 
CA. Pyr, pyramidal cell layer of CA. iv, v) Co-localization of CB1R mRNA and BiP mRNA 1127 
in cells of the polymorphic layer (Pl). Gr, granular cell layer. Sections were hybridized 1128 
with 33P-labelled probes for CB1R mRNA (signal visualized as clusters of bright silver 1129 
grains in dark field images) and with digoxigenin-labelled probes for BiP mRNA (signal 1130 
visualized as dark precipitate in bright field images). Arrows point to some double-1131 
labelled cells. D, Quantification of CB1R mRNA-positive cells that co-express BiP mRNA 1132 
(n=4 mice per group). 1133 
 1134 
Fig 5. Co-localization of BiP mRNA with GAD65/67 or vGlut1 mRNA in the mouse 1135 
hippocampus 1136 
A, Representative mosaic superimages of sections from the adult mouse hippocampus 1137 
that were hybridized with 33P-labelled probes for BiP mRNA (signal visualized as 1138 
clusters/accumulation of bright silver grains in the dark field image i) and with a mixture 1139 
of digoxigenin-labelled probes for GAD65 and GAD67 mRNAs (labelled cells showing 1140 
dark precipitate in the bright field image ii). Higher magnification images of cornu 1141 




Arrows point to some double-labelled cells, while arrowheads point to some cells that 1143 
express BiP mRNA but not GAD65/67 mRNA. B, Quantification of BiP mRNA-positive 1144 
cells that co-express GAD65/67 mRNA (n=4 mice per group). C, Representative mosaic 1145 
superimages of sections from the adult mouse hippocampus that were hybridized with 1146 
33P-labelled probes for BiP mRNA (signal visualized as clusters/accumulation of bright 1147 
silver grains in the dark field image i) and with digoxigenin-labelled probes for vGluT1 1148 
mRNA (labelled cells showing dark precipitate in the bright field image ii). Higher 1149 
magnification images of CA (images iii and iv) and DG (images v and vi) are shown. 1150 
Arrows point to some double-labelled cells, while arrowheads point to some cells that 1151 
express BiP mRNA but not vGluT1 mRNA. D, Quantification of BiP mRNA-positive cells 1152 
that co-express vGluT1 mRNA (n=4 mice per group). 1153 
 1154 
Figure 6. Subcellular localization of BiP in the mouse brain 1155 
A, Western blotting of BiP in total-extract (T), cytosolic (C) and endoplasmic reticulum 1156 
(ER) fractions from the hippocampus, striatum and cortex of 3-4 month-old WT mice. 1157 
Calnexin was included as an ER-specific marker. Representative blots from 2 mice are 1158 
shown. B, Quantification of BiP levels in the C and ER fractions relative to BiP levels in 1159 
the T fraction. **p<0.01 from the corresponding ER fraction by one-way ANOVA with 1160 
Tukey’s multiple comparisons test (n=3-4 mice per group). C, PLA experiments 1161 
conducted on synaptosomal fractions isolated from the hippocampus, striatum and 1162 
cortex of 3-4 month-old CB1R-WT and CB1R-KO mice. Representative images of 1163 
hippocampal (left column), striatal (mid column) and cortical (right column) 1164 






Figure 7. CB1R-BiP complexes reside on GABAergic terminals of the mouse 1168 
hippocampus 1169 
A, PLA experiments were conducted on hippocampal sections from 3-4-month-old mice 1170 
of different genotypes. Representative low-magnification image and selected regions for 1171 
analysis are shown. Image credit: Allen Institute. In the rest of the panels, CB1R-BiP 1172 
complexes are shown as red dots, and nuclei are colored in blue by DAPI staining. B, 1173 
Representative images of dentate gyrus (DG) sections from CB1R-floxed, CB1R-KO, 1174 
GABA-CB1R-KO and Glu-CB1R-KO mice. C, Representative images of DG sections 1175 
from Stop-CB1R, CB1R-RS, GABA-CB1R-RS and Glu-CB1R-RS mice. D, Quantification 1176 
of the number of cells containing one or more dots expressed as the percentage of the 1177 
total number of cells (DAPI-stained nuclei) in DG sections. **p<0.01 from the 1178 
corresponding CB1R-floxed group or the corresponding CB1R-RS group by one-way 1179 
ANOVA with Tukey’s multiple comparisons test (n=6-7 fields from three different animals 1180 
per group). E, Representative images of CA1 sections from CB1R-floxed, CB1R-KO, 1181 
GABA-CB1R-KO and Glu-CB1R-KO mice. F, Representative images of CA1 sections 1182 
from Stop-CB1R, CB1R-RS, GABA-CB1R-RS and Glu-CB1R-RS mice. G, Quantification 1183 
of the number of cells containing one or more dots expressed as the percentage of the 1184 
total number of cells (DAPI-stained nuclei) in CA1 sections. **p<0.01 from the 1185 
corresponding CB1R-floxed group or the corresponding CB1R-RS group by one-way 1186 
ANOVA with Tukey’s multiple comparisons test (n=6-7 fields from three different animals 1187 
per group). 1188 
 1189 
Figure 8. CB1R-BiP complexes reside on GABAergic terminals of the mouse 1190 
striatum and cortex 1191 




mice of different genotypes. Representative low-magnification image and selected 1193 
regions for analysis are shown. Image credit: Allen Institute. In the rest of the panels, 1194 
CB1R-BiP complexes are shown as red dots, and nuclei are colored in blue by DAPI 1195 
staining. B, Representative images of striatal sections from CB1R-floxed, CB1R-KO, 1196 
GABA-CB1R-KO and Glu-CB1R-KO mice. C, Representative images of striatal sections 1197 
from Stop-CB1R, CB1R-RS, GABA-CB1R-RS and Glu-CB1R-RS mice. D, Quantification 1198 
of the number of cells containing one or more dots expressed as the percentage of the 1199 
total number of cells (DAPI-stained nuclei) in striatal sections. **p<0.01 from the 1200 
corresponding CB1R-floxed group or the corresponding CB1R-RS group by one-way 1201 
ANOVA with Tukey’s multiple comparisons test (n=6-7 fields from three different animals 1202 
per group). E, Representative images of cortical sections from CB1R-floxed, CB1R-KO, 1203 
GABA-CB1R-KO and Glu-CB1R-KO mice. F, Representative images of cortical sections 1204 
from Stop-CB1R, CB1R-RS, GABA-CB1R-RS and Glu-CB1R-RS mice. G, Quantification 1205 
of the number of cells containing one or more dots expressed as the percentage of the 1206 
total number of cells (DAPI-stained nuclei) in cortical sections. **p<0.01 from the 1207 
corresponding CB1R-floxed group or the corresponding CB1R-RS group by one-way 1208 
ANOVA with Tukey’s multiple comparisons test (n=6-7 fields from three different animals 1209 
per group). 1210 
 1211 
Figure 9. BiP does not affect CB1R-evoked hypolocomotion, analgesia, 1212 
hypothermia and catalepsy in vivo 1213 
A, Scheme of the experiments. Vehicle or THC (10 mg/kg, 1 i.p. injection per day) was 1214 
administered for 5 days to 3-4 month-old BiP+/+ (BiP-WT) and BiP+/- (BiP-HET) mice. The 1215 
“cannabinoid tetrad” was evaluated on days 1 and 5, starting 30 min after the 1216 




open-field test on day 1 (left panel) and day 5 (right panel). C, Analgesia (latency to pain, 1218 
s) in the hot-plate test on day 1 (left panel) and day 5 (right panel). D, Hypothermia 1219 
(change in body temperature, °C) as measured with a rectal thermometer on day 1 (left 1220 
panel) and day 5 (right panel). E, Catalepsy (latency to move, s) as measured on a 1221 
horizontal bar on day 1 (left panel) and day 5 (right panel). In panels B thru E, **p<0.01 1222 
from the corresponding vehicle group, or ##p<0.01 from the BiP-WT-vehicle group, by 1223 
two-way ANOVA with Tukey’s multiple comparisons test (panel B, n=18-20 mice per 1224 
group; panels C, D and E, n=9-10 mice per group). 1225 
 1226 
Figure 10. BiP modulates CB1R-evoked anxiety in vivo 1227 
Anxiety-like behaviors were measured on an experimental scheme similar to that shown 1228 
in Fig. 9A. A, Anxiety (normalized entries in the center, m-1) in the open-field (OF) test on 1229 
day 1 (left panel) and day 5 (right panel). Arenas (with their centers outlined in red) 1230 
illustrating the ambulation of a representative animal per group on day 5 are shown 1231 
(lower panel). B, Anxiety (left panel: number of entries in the open arms; right panel: 1232 
time spent in the open arms, %) in the elevated plus maze (EPM) test on day 1. In 1233 
panels A and B, *p<0.05, **p<0.01 from the corresponding vehicle group, or #p<0.05, 1234 
##p<0.01 from the BiP-WT-vehicle group, by two-way ANOVA with Tukey’s multiple 1235 
comparisons test (panel A, n=18-20 mice per group; panel B, n=22-28 mice per group). 1236 




Table legends 1238 
 1239 
Table 1. Oligonucleotides used for in situ hybridization histochemistry 1240 
 1241 
Table 2. Effect of CB1R-CTD phosphomimetic mutants on CB1R-BiP interaction 1242 
Scheme of the Y2H experiment using every possible single phosphomimetic mutant 1243 
(S/T→D) within CB1R-CTD as bait, and BiP-IR as prey. Only one clone abrogated the 1244 











bp limits Oligonucleotide sequence 
mCB1/1 Cannabinoid receptor 1 U22948.1  186-230 GATGGTACGGAAGGTGGTATCTGCAAGGCCGTCTAAGATCGACTT 
mCB1/2 Cannabinoid receptor 1 U22948.1  556-600 ATAGCACCAGCAGGTTCTCCAGAACCGTGAAGGTGCCCAGGGTGA 
mCB1/3 Cannabinoid receptor 1 U22948.1  1556-1601 CAGAGCCTCGGCAGACGTGTCTGTGGACACAGACATGGTCACCTT 
mGRP78/1 78 kDa glucose-regulated protein (BiP) D78645.1 121-165 TCTTGTCCTCCTCCTCGGCCCGCACCGCGCCCAGCAGCAGCAACG 
mGRP78/2 78 kDa glucose-regulated protein (BiP) D78645.1 1262-1306 ACACCAGCCTGGACAGCGGCACCATAGGCTACAGCCTCATCGGGG 
mGRP78/3 78 kDa glucose-regulated protein (BiP) D78645.1 1996-2040 ATGTATCCTCTTCACCAGTTGGGGGAGGGCCTCCACTTCCATAGA 
rmGAD65/1 Glutamic acid decarboxylase 65 NM_008078.2 421-465 CTTGTTTCCGATGCCGCCCGTGAACTTTTGGGCCACCTGGCACCA 
rmGAD65/2 Glutamic acid decarboxylase 65 NM_008078.2 776-820 GCGTCAAAATTTCCTCCAGATTTTGCGGTTGGTCTGCCAATTCCC 
rGAD/5 Glutamic acid decarboxylase 67 M76177.1 1601-1654 ATAGAGGTATTCAGCCAGCTCCAGGCATTTGTTGATCTGATTTTCAAATCCCAC 
rVGluT1/1 Vesicular GluT1 Transporter NM_053859.1 127-171 CAGGGCGCGCCCCGCCAGCTTCCGAAACTCCTCCTGCCGGAACTC 




Table 2. Effect of CB1R-CTD phosphomimetic mutants on CB1R-BiP interaction 
Scheme of the Y2H experiment using every possible single phosphomimetic mutant 
(S/T→D) within CB1R-CTD as bait, and BiP-IR as prey. Only one clone abrogated the 
interaction (CB1R-CTD-S452D). 
 
Bait plasmid Prey plasmid Interaction 
pGBT9 CB1R-CTD-S410D pACT2 BiP-IR + (n=3) 
pGBT9 CB1R-CTD-S414D pACT2 BiP-IR + (n=3) 
pGBT9 CB1R-CTD-T418D pACT2 BiP-IR + (n=3) 
pGBT9 CB1R-CTD-S425D pACT2 BiP-IR + (n=3) 
pGBT9 CB1R-CTD-S429D pACT2 BiP-IR + (n=3) 
pGBT9 CB1R-CTD-S441D pACT2 BiP-IR + (n=3) 
pGBT9 CB1R-CTD-S448D pACT2 BiP-IR + (n=3) 
pGBT9 CB1R-CTD-S452D pACT2 BiP-IR – (n=3) 
pGBT9 CB1R-CTD-T453D pACT2 BiP-IR + (n=3) 
pGBT9 CB1R-CTD-T460D pACT2 BiP-IR + (n=3) 
pGBT9 CB1R-CTD-S462D pACT2 BiP-IR + (n=3) 
pGBT9 CB1R-CTD-S464D pACT2 BiP-IR + (n=3) 
pGBT9 CB1R-CTD-T465D pACT2 BiP-IR + (n=3) 
pGBT9 CB1R-CTD-T467D pACT2 BiP-IR + (n=3) 
pGBT9 CB1R-CTD-S468D pACT2 BiP-IR + (n=3) 
 










